NCT05736731
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05736731
Title A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1)
Acronym EVEREST-1
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors A2 Biotherapeutics Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Banner Health Gilbert Arizona 85234 United States Details
University of California San Diego La Jolla California 92093 United States Details
UCLA Medical Center Los Angeles California 90404 United States Details
Moffitt Cancer Center Tampa Florida 33136 United States Details
Mayo Clinic Rochester Rochester Minnesota 55905 United States Details
Washington University St Louis Missouri 63110 United States Details
NYU Langone Medical Center New York New York 10016 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field